Zacks upgraded Rapport Therapeutics to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The rating change could produce modest upside in the stock (likely low-single-digit percentage moves) as investor sentiment improves, though no new financials or guidance were disclosed.
Zacks upgraded Rapport Therapeutics to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The rating change could produce modest upside in the stock (likely low-single-digit percentage moves) as investor sentiment improves, though no new financials or guidance were disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
